We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Great find mate
Hmmm... post from October 5th ‘this is not a get rich quick share’ posted when the share price was 83p ‘farn’ is worth 55p and is a ‘strong sell’. Although I think £25 is in the short term is a little ambitious, I think that is more of a likely scenario than FARN is worth 55p. Also what is a get rich share? Farn has come from 83p (October) to £5 in (April) it’s certainly been ‘get rich’ quickly Share for me! Happy days!
I think people seriously underestimate this company,Clevegen,on its own could be worth 10 quid a share,cancer exterminator 44%shrinkage from 2 injections,then Traumakine,the sky’s the limit,with ARDS,and the coved 19,virus complications it causes.Then the secret weapon,awesome share,who knows how high it will go,when partners jump in,exciting
No TC101 I did not purchase any shares in Kodak. greggreen, I still think that this is not a get rich quick share especially with the likes of SNG about. I'm interested in your response to Zen's numerous £25 share price predictions and I think he also predicted a £25 Dividend as well.
Oscar - i think and from the evidence, you should 'Get back in the sea', and wind your neck back in and go spout some nonsense on another BB.
Good day, and stay at home and stay away in general. Did you buy shares in Kodak?
Brilliant find my freind
OscarAim
12 Mar 2020 09:12
'This is certainly not a get rich quick share' ... Price: 272.50
Today ... Price: 500.00
Filtered
Oscar -hopefully both drugs will be useful and all of us will see decent returns (like many of us already have), but SNG from what i can see is a one trick pony, Faron has more in development. So you may have a spanner like we do although i think we have a hammer, and we have a tool box!
Dont think so.
Traumakine is dealing with ARDS
Different class altogether.. that's why they have been selected for the Remap cap worldwide trials
SNG could through a major spanner in the works for FARON
Let's stop comparing which is better between traumakine and sng drug. I hope they both are effective for the sake of saving lives.
Also if both are effective it backs up that Interferon beta-1a is the answer, so it is in both companies interest that each succeeds. Demand will be high enough that both will be utilised if effective.
I think doctors preference would be for traumakine as when a patient is critically ill IV might be the only reliable delivery method. But as above, there would be demand for both drugs as there won't be enough traumakine in stock to satisfy immediate GLOBAL demand.
Folks - please keep it real!
Be kind.
Itsall...give a rest or put the wine down...do you think that's what SNG have done for the last 5 years? Instead of playing my dick's bigger than your dick, you should be pleased that another company has a different application using the same molecule...it shows it's working in different ways...not going to waste any more time with you..all respect lost
It's not just a case of sticking interferon b in a inhaler and blowing it into someone's lungs.
Through extensive research and ex-vivo studies, scientists at Turku University have identified, that a molecule called CD73 is an essential entity needed to maintain endothelial barrier function. One of the key findings that led to the development of Traumakine was a discovery that interferon beta-1a could enhance CD73 expression and therefore could be used to treat a range of vascular leakage conditions, including ARDS. Traumakine works by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine so that vascular leaking and escalation of inflammation are reduced.
"The interferon beta-1 formulation will be delivered intravenously, which he says offers the best “delivery route” for critically ill patients"